Inhibition of matrix metalloproteinase-2 by halofuginone is mediated by the Egr1 transcription factor

Anti-Cancer Drugs

Volumn 23, Issue 10, 2012, Pages 1022-1031

  Zcharia, Eyal ^a   Atzmon, Ruth ^a   Nagler, Adi ^a   Shimoni, Avichai ^b   Peretz, Tamar ^a   Vlodavsky, Israel ^c   Nagler, Arnon ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

anticancer drug; breast carcinoma; Egr1 transcription factor; halofuginone; matrix metalloproteinase

Indexed keywords

COREPRESSOR PROTEIN; EARLY GROWTH RESPONSE FACTOR 1; GELATINASE A; HALOFUGINONE; NAB 2 PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CELL MDA MB 435; CANCER INHIBITION; CELL LINE; CHROMATIN IMMUNOPRECIPITATION; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN BINDING; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; UPREGULATION; WESTERN BLOTTING; ZYMOGRAPHY;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; EARLY GROWTH RESPONSE PROTEIN 1; FEMALE; GENE EXPRESSION; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE INHIBITORS; PIPERIDINES; PROMOTER REGIONS, GENETIC; QUINAZOLINONES; REPRESSOR PROTEINS; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 84867583167     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328357d186     Document Type: Article

References (52)

1. Granot I, Bartov I, Plavnik I, Wax E, Hurwitz S, Pines M. Increased skin tearing in broilers and reduced collagen synthesis in skin in vivo and in vitro in response to the coccidiostat halofuginone. Poult Sci 1991; 70: 1559-1563.
2. Pines M, Snyder D, Yarkoni S, Nagler A. Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Biol Blood Marrow Transplant 2003; 9:417-425.
3. Bruck R, Genina O, Aeed H, Alexiev R, Nagler A, Avni Y, et al. Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Hepatology 2001; 33:379-386.
4. Pines M, Knopov V, Genina O, Lavelin I, Nagler A. Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine- induced liver cirrhosis. J Hepatol 1997; 27:391-398.
5. Levi-Schaffer F, Nagler A, Slavin S, Knopov V, Pines M. Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice: Effect of halofuginone. J Invest Dermatol 1996; 106:84-88.
6. Nagler A, Firman N, Feferman R, Cotev S, Pines M, Shoshan S. Reduction in pulmonary fibrosis in vivo by halofuginone. Am J Respir Crit Care Med. 1996; 154:1082-1086.
7. Elkin M, Ariel I, Miao HQ, Nagler A, Pines M, de-Groot N, et al. Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone. Cancer Res 1999; 59:4111-4118.
8. Gross DJ, Reibstein I, Weiss L, Slavin S, Dafni H, Neeman M, et al. Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo. Clin Cancer Res 2003; 9: 3788-3793.
9. Gavish Z, Pinthus JH, Barak V, Ramon J, Nagler A, Eshhar Z, et al. Growth inhibition of prostate cancer xenografts by halofuginone. Prostate 2002; 51:73-83.
10. Nagler A, Ohana M, Shibolet O, Shapira MY, Alper R, Vlodavsky I, et al. Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginone. Eur J Cancer 2004; 40:1397-1403.
11. Abramovitch R, Itzik A, Harel H, Nagler A, Vlodavsky I, Siegal T. Halofuginone inhibits angiogenesis and growth in implanted metastatic rat brain tumor model - an MRI study. Neoplasia 2004; 6:480-489.
12. Pinthus JH, Sheffer Y, Nagler A, Fridman E, Mor Y, Genina O, et al. Inhibition of Wilms tumor xenograft progression by halofuginone is accompanied by activation of WT-1 gene expression. J Urol 2005; 174:1527-1531.
13. Elkin M, Miao HQ, Nagler A, Aingorn E, Reich R, Hemo I, et al. Halofuginone: A potent inhibitor of critical steps in angiogenesis progression. FASEB J 2000; 14:2477-2485.
14. Elkin M, Reich R, Nagler A, Aingorn E, Pines M, de-Groot N, et al. Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone. Clin Cancer Res 1999; 5:1982-1988.
15. Kessenbrock K, Plaks V,Werb Z. Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell 2012; 141:52-67.
16. Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: Outside-in signaling and relationship to tumor progression. Biochim Biophys Acta 2012; 1825:29-36.
17. Deryugina EI, Quigley JP. Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: Contrasting, overlapping and compensatory functions. Biochim Biophys Acta 2012; 1803:103-120.
18. Baron V, De Gregorio G, Krones-Herzig A, Virolle T, Calogero A, Urcis R, et al. Inhibition of Egr-1 expression reverses transformation of prostate cancer cells in vitro and in vivo. Oncogene 2003; 22:4194-4204.
19. Taras D, Blanc JF, Rullier A, Dugot-Senant N, Laurendeau I, Bieche I, et al. Halofuginone suppresses the lung metastasis of chemically induced hepatocellular carcinoma in rats through MMP inhibition. Neoplasia 2006; 8:312-318.
20. Harja E, Chang JS, Lu Y, Leitges M, Zou YS, Schmidt AM, et al. Mice deficient in PKCbeta and apolipoprotein E display decreased atherosclerosis. FASEB J 2009; 23:1081-1091.
21. Bouchard F, Belanger SD, Biron-Pain K, St-Pierre Y. EGR-1 activation by EGF inhibits MMP-9 expression and lymphoma growth. Blood 2012; 116:759-766.
22. Thiel G, Cibelli G. Regulation of life and death by the zinc finger transcription factor Egr-1. J Cell Physiol 2002; 193:287-292.
23. Gnainsky Y, Spira G, Paizi M, Bruck R, Nagler A, Genina O, et al. Involvement of the tyrosine phosphatase early gene of liver regeneration (PRL-1) in cell cycle and in liver regeneration and fibrosis effect of halofuginone. Cell Tissue Res 2006; 324:385-394.
24. Russo MW, Sevetson BR, Milbrandt J. Identification of NAB1, a repressor of NGFI-A- and Krox20-mediated transcription. Proc Natl Acad Sci USA 1995; 92:6873-6877.
25. Sevetson BR, Svaren J, Milbrandt J. A novel activation function for NAB proteins in EGR-dependent transcription of the luteinizing hormone beta gene. J Biol Chem 2000; 275:9749-9757.
26. Svaren J, Sevetson BR, Apel ED, Zimonjic DB, Popescu NC, Milbrandt J. NAB2, a corepressor of NGFI-A (Egr-1) and Krox20, is induced by proliferative and differentiative stimuli. Mol Cell Biol 1996; 16:3545-3553.
27. Edovitsky E, Elkin M, Zcharia E, Peretz T, Vlodavsky I. Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl Cancer Inst 2004; 96:1219-1230.
28. Shteper PJ, Zcharia E, Ashhab Y, Peretz T, Vlodavsky I, Ben-Yehuda D. Role of promoter methylation in regulation of the mammalian heparanase gene. Oncogene 2003; 22:7737-7749.
29. Zcharia E, Jia J, Zhang X, Baraz L, Lindahl U, Peretz T, et al. Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases. PLoS One 2009; 4:e5181.
30. Luca M, Huang S, Gershenwald JE, Singh RK, Reich R, Bar-Eli M. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol 1997; 151:1105-1113.
31. Reich R, Blumenthal M, Liscovitch M. Role of phospholipase D in laminininduced production of gelatinase A (MMP-2) in metastatic cells. Clin Exp Metastasis 1995; 13:134-140.
32. Cohen I, Maly B, Simon I, Meirovitz A, Pikarsky E, Zcharia E, et al. Tamoxifen induces heparanase expression in estrogen receptor-positive breast cancer. Clin Cancer Res 2007; 13:4069-4077.
33. Meirovitz A, Hermano E, Lerner I, Zcharia E, Pisano C, Peretz T, et al. Role of heparanase in radiation-enhanced invasiveness of pancreatic carcinoma. Cancer Res 2012; 71:2772-2780.
34. Sze KM, Wong KL, Chu GK, Lee JM, Yau TO, Oi-Lin Ng I. Loss of phosphatase and tensin homolog enhances cell invasion and migration through AKT/Sp-1 transcription factor/matrix metalloproteinase 2 activation in hepatocellular carcinoma and has clinicopathologic significance. Hepatology 2012; 53:1558-1569.
35. Elkin M, Cohen I, Zcharia E, Orgel A, Guatta-Rangini Z, Peretz T, et al. Regulation of heparanase gene expression by estrogen in breast cancer. Cancer Res 2003; 63:8821-8826.
36. Zcharia E, Philp D, Edovitsky E, Aingorn H, Metzger S, Kleinman HK, et al. Heparanase regulates murine hair growth. Am J Pathol 2005; 166: 999-1008.
37. Houston P, Campbell CJ, Svaren J, Milbrandt J, Braddock M. The transcriptional corepressor NAB2 blocks Egr-1-mediated growth factor activation and angiogenesis. Biochem Biophys Res Commun 2001; 283:480-486.
38. Lucerna M, Mechtcheriakova D, Kadl A, Schabbauer G, Schafer R, Gruber F, et al. NAB2, a corepressor of EGR-1, inhibits vascular endothelial growth factor-mediated gene induction and angiogenic responses of endothelial cells. J Biol Chem 2003; 278:11433-11440.
39. Qu Z, Wolfraim LA, Svaren J, Ehrengruber MU, Davidson N, Milbrandt J. The transcriptional corepressor NAB2 inhibits NGF-induced differentiation of PC12 cells. J Cell Biol 1998; 142:1075-1082.
40. De Mestre AM, Khachigian LM, Santiago FS, Staykova MA, Hulett MD. Regulation of inducible heparanase gene transcription in activated T cells by early growth response 1. J Biol Chem 2003; 278:50377-50385.
41. De Mestre AM, Rao S, Hornby JR, Soe-Htwe T, Khachigian LM, Hulett MD. Early growth response gene 1 (EGR1) regulates heparanase gene transcription in tumor cells. J Biol Chem 2005; 280:35136-35147.
42. De Mestre AM, Staykova MA, Hornby JR, Willenborg DO, Hulett MD. Expression of the heparan sulfate-degrading enzyme heparanase is induced in infiltrating CD4+ T cells in experimental autoimmune encephalomyelitis and regulated at the level of transcription by early growth response gene 1. J Leukoc Biol 2007; 82:1289-1300.
43. De FigueiredoPontes LL, Assis PA, Santana-Lemos BA, Jacomo RH, Lima AS, Garcia AB, et al. Halofuginone has anti-proliferative effects in acute promyelocytic leukemia by modulating the transforming growth factor beta signaling pathway. PLoS One 2012; 6:e26713.
44. Leiba M, Jakubikova J, Klippel S, Mitsiades CS, Hideshima T, Tai YT, et al. Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents. Br J Haematol 2012; 157:718-731.
45. Yee KO, Connolly CM, Pines M, Lawler J. Halofuginone inhibits tumor growth in the polyoma middle T antigen mouse via a thrombospondin-1 independent mechanism. Cancer Biol Ther 2006; 5:218-224.
46. Jordan MC, Zeplin PH. Local inhibition of angiogenesis by halofuginone coated silicone materials. J Mater Sci Mater Med 2012; 23:1203-1210.
47. Brown S, Meroueh SO, Fridman R, Mobashery S. Quest for selectivity in inhibition of matrix metalloproteinases. Curr Top Med Chem 2004; 4: 1227-1238.
48. Ning W, Li CJ, Kaminski N, Feghali-Bostwick CA, Alber SM, Di YP, et al. Comprehensive gene expression profiles reveal pathways related to the pathogenesis of chronic obstructive pulmonary disease. Proc Natl Acad Sci USA 2004; 101:14895-14900.
49. Velculescu VE, Zhang L, Vogelstein B, Kinzler KW. Serial analysis of gene expression. Science 1995; 270:484-487.
50. Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 2006; 38:2018-2039.
51. Manon-Jensen T, Itoh Y, Couchman Jr. Proteoglycans in health and disease: The multiple roles of syndecan shedding. FEBS J 2012; 277: 3876-3889.
52. Purushothaman A, Chen L, Yang Y, Sanderson RD. Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J Biol Chem 2008; 283:32628-32636.